New Castle Disease Virus(Hadassah University Hospital)(New Castle Disease Virus(Hadassah University Hospital))

概要

基本信息

药物类型

溶瘤病毒

别名-

靶点-

作用方式-

作用机制-

治疗领域-

在研适应症-

非在研适应症-

原研机构

Hadassah University Hospital

在研机构-

非在研机构

Hadassah University Hospital

权益机构-

最高研发阶段终止临床1/2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

1

项与 New Castle Disease Virus(Hadassah University Hospital) 相关的临床试验

NCT01174537

/ Withdrawn临床1/2期IIT

Clinical Application of Intravenous New Castle Disease Virus - HUJ Oncolytic Virus in the Treatment of Advanced Glioblastoma Multiforme, Soft and Bone Sarcomas and Neuroblastoma Patients, Resistant to Conventional Anti- Cancer Modalities

Patients with specific metastatic cancers who failed prior therapeutic regimes will be treated with NDV for at least a year or until disease progression. The study will measure progression-free disease and posits that it will be extended.

开始日期2011-07-01

申办/合作机构

Hadassah University Hospital

100 项与 New Castle Disease Virus(Hadassah University Hospital) 相关的临床结果

登录后查看更多信息

100 项与 New Castle Disease Virus(Hadassah University Hospital) 相关的转化医学

登录后查看更多信息

100 项与 New Castle Disease Virus(Hadassah University Hospital) 相关的专利（医药）

登录后查看更多信息

100 项与 New Castle Disease Virus(Hadassah University Hospital) 相关的药物交易

登录后查看更多信息